Parthanatos

Parthanatos is a form of programmed cell death that is distinct from apoptosis and necrosis. It is initiated by overactivation of the nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1) in response to severe DNA damage, oxidative stress, or excitotoxic events. Unlike apoptosis, parthanatos is caspase-independent and relies on the formation of poly(ADP-ribose) (PAR) polymers and subsequent mitochondrial dysfunction leading to the nuclear translocation of apoptosis-inducing factor (AIF).

Mechanism and features: Excess PARP-1 activity depletes cellular NAD+ and ATP, causing energy failure. PAR polymers accumulate and promote the release of AIF from mitochondria. AIF then translocates to the nucleus where it participates in large-scale DNA fragmentation and chromatin condensation, culminating in cell death. The process can involve interactions with nuclear nucleases such as MIF and is considered PAR-dependent. Parthanatos is characterized by PAR accumulation and AIF-dependent, caspase-independent cell death, rather than the caspase-driven processes typical of apoptosis.

Biological and clinical relevance: Parthanatos has been implicated in neuronal injury, including ischemia-reperfusion injury and certain neurodegenerative conditions. It is studied as a potential target for neuroprotection, since PARP inhibitors can block PAR synthesis and prevent AIF release in experimental models. The pathway represents a separate axis of regulated cell death that can operate alongside other death mechanisms under stress.

Detection and terminology: The term parthanatos combines PAR involvement with a death process, reflecting its reliance on PAR metabolism and AIF-mediated nuclear responses. Its identification in studies typically involves evidence of PAR accumulation, AIF translocation, and caspase independence.